Siemens Medical Solutions and Chongqing Haifu (HAIFU) Technology Co., Ltd have signed a contract to jointly develop an MRI guided High Intensity Focused Ultrasound (HIFU) therapy system. Aim of the collaboration is to combine Haifu’s leading therapy technology with Siemens’ expertise in high field Magnetic Resonance Imaging (MRI). With help of this new method the main applications will focus on women’s health treatments like benign uterine fibroids and cancer as well as malignant and benign tumors of liver, kidney, pancreas and bone. The joint development of an MR-guided HIFU treatment solution fits logically into the Siemens strategy to expand Siemens’ solution offerings, providing not only excellent diagnostic accuracy but also innovative image-guided therapy solutions world-wide.
The combination of HIFU with MRI not only gives improved visualization of tumor morphology but also more precise thermal dose control, which will eventually speed up treatment times even further. The collaboration between Siemens and HAIFU includes the ability to precisely and robustly visualize temperature distributions inside the human body. Further developments involve MR applications for diagnosis, therapy planning as well as outcome assessment. Patient treatment will be performed on a special HIFU patient bed inside the bore of Siemens’ range of high field scanners. For example Magnetom Espree’s Open Bore of 70 centimeter will offer maximum freedom in patient positioning in order to enable a better HIFU beam access to the tumor location and consequently more efficient treatment. For uterine fibroid treatment we are aiming at sonication times below one hour.
Haifu is a world-wide leader in non-invasive HIFU treatment. Haifu has 17 years experience with HIFU as a therapeutic modality. More than 6,000 patients have been treated on Haifu products in Europe and Asia. The company offers a broad spectrum of applications in research and clinical practice. Tumors that have been successfully treated include primary liver cancer, soft tissue sarcoma, pancreatic cancer, renal cancer as well as, metastases. Haifu has developed the first non-invasive limb-salvaging treatment for patients with bone tumors and HIFU breast-preserving treatment for patients with breast cancer.
Treatment using HIFU is already used in daily hospital practice around the world, mostly using ultrasound as the guided imaging modality. The excellent clinical outcome has been documented in more than 25 international peer reviewed publications. HIFU has been proposed as a therapeutic method since the 1950s. However, the inability to treat large tissue volumes in short times with good visualization of the target volume has hampered the clinical acceptance of the technique. However, Haifu has been able to develop a technology which overcomes these major limitations.
Professor Zhibiao Wang, President of Haifu stated “Chongqing Haifu is very pleased about the cooperation with Siemens which is seen as a strong partner for offering HIFU treatment to patients throughout the world. We have had great international success with US-guided HIFU treatment but we believe that MR-guided HIFU will provide an added direction and more options with Siemens advanced MR technology and offer more exciting developments for the future of HIFU technology.
”Siemens has been developing HIFU technology since 1993. Combining Siemens MR integration technology with Haifu's unmatched clinical expertise in non-invasive, fast HIFU protocols we will make a new quality of tumor treatment available to many seriously ill patients,” said Dr. Heinrich Kolem, President of Siemens MR.
Chongqing Haifu (HIFU) Technology Co. Ltd.
is a manufacturer of medical devices specialized in developing Therapeutic Ultrasound Systems based in Chongqing, PRC, and founded in 1987. The company employs 200 people. Research and Development, Production, Sales & Marketing and the International Department are all located in house where they focus on research, manufacturing and clinical applications development. The company has its own Clinical Center for Tumor Therapy and cooperates with the Institute of Ultrasound Engineering in Medicine at Chongqing University of Medical Sciences. After 17 years of research, Haifu has developed and produced a series of products such as the JC Extracorporeal Focused Ultrasound Tumor Therapy System or the CZF Therapeutic System for Gynaecological Diseases (Seapostar).
More information about Haifu can be found at www.haifu.com.cn
Siemens Medical Solutions
is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. From imaging systems for diagnosis, to therapy equipment for treatment, to patient monitors to hearing instruments and beyond, Siemens innovations contribute to the health and well-being of people across the globe, while improving operational efficiencies and optimizing workflow in hospitals, clinics, home health agencies, and doctors' offices. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.61 billion EUR and group profit of about 1 billion EUR for fiscal 2005 (preliminary figures). Further information can be found under: www.siemens.com/medical